跳转至内容
Merck
CN

124018

Akt抑制剂VIII,同工酶选择性,Akti-1/2

Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2, CAS 612847-09-3, is a cell-permeable, reversible inhibitor of Akt1/Akt2 (IC50 = 58 nM, 210 nM, & 2.12 µM for Akt1, Akt2, and Akt3, respectively).

别名:

Akt抑制剂VIII,同工酶选择性,Akti-1/2

登录 查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C34H29N7O
化学文摘社编号:
分子量:
551.64
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.28
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

质量水平

方案

≥95% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
protect from light

颜色

yellow

溶解性

DMSO: 5 mg/mL

运输

ambient

储存温度

2-8°C

SMILES字符串

N6(CCC(CC6)[n]7c8c(nc7O)cccc8)Cc1ccc(cc1)c2nc3c(nc2c5ccccc5)cc4[nH]cnc4c3

InChI

1S/C34H29N7O/c42-34-39-26-8-4-5-9-31(26)41(34)25-14-16-40(17-15-25)20-22-10-12-24(13-11-22)33-32(23-6-2-1-3-7-23)37-29-18-27-28(36-21-35-27)19-30(29)38-33/h1-13,18-19,21,25H,14-17,20H2,(H,35,36)(H,39,42)

InChI key

BIWGYFZAEWGBAL-UHFFFAOYSA-N

一般描述

Akt1/Akt2活性的细胞可渗透,可逆,有效和选择性抑制剂(在体外激酶测定中,Akt1,Akt2和Akt3的IC50分别为58 nM,210 nM和2.12 µM)。据报道抑制作用具有普列克底物蛋白同源物(PH)域依赖性。即使在50 µM的高浓度情况下,它也不会对缺乏PH结构域的Akt或其他紧密相关的AGC家族激酶,PKA,PKC和SGK表现出任何抑制作用。克服了Akt1/Akt2介导的肿瘤细胞对化学疗法的抗性并显示出在体外培养的细胞和体内小鼠中均能阻断Akt1/Akt2的基础和刺激的磷酸化/激活。
一种可渗透细胞且可逆的喹喔啉化合物,可有效选择性地抑制Akt1/Akt2活性(在体外激酶测定中,Akt1,Akt2和Akt3的IC50分别为58 nM,210 nM和2.12 µM)。抑制作用似乎具有普列克底物蛋白同源物(PH)域依赖性。即使在50 µM的高浓度情况下,它也不会对缺乏PH结构域的Akt或其他紧密相关的AGC家族激酶,PKA,PKC和SGK表现出任何抑制作用。克服了Akt1/Akt2介导的肿瘤细胞对化学疗法的抗性并显示出在体外培养的细胞和体内小鼠中均能阻断Akt1/Akt2的基础和刺激的磷酸化/激活。也可获得10 mM(1 mg/181 µl)Akt抑制剂VIII,同工酶选择性,Akti-1/2(目录号124017)在DMSO中的溶液。

生化/生理作用

主要靶标
Akt1, Akt2, Akt3
产物不与ATP竞争。
可逆性:是
细胞可渗透性:是
靶标IC50:在体外激酶测定中,Akt1,Akt2和Akt3分别为58 nM,210 nM和2.12 µM

包装

用惰性气体包装

制备说明

在复溶后,分装并冷冻保存(-70°C)。储备液可在-70°C最长稳定6个月。

其他说明

Calleja, V., et al. 2009.PLoS Biol.7, e17.
Logie, L., et al. 2007.Diabetes56, 228.
Barnett, S.F., et al. 2005.Biochem.J.385, 399.
DeFeo-Jones, D., et al. 2005.Mol.Cancer Ther.4, 271.
Zhao, Z., et al. 2005.Bioorg.Med. Chem. Lett.15, 905.
Lindsley, C.W., et al. 2005.Bioorg.Med. Chem. Lett.15, 761.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

毒性:标准处理(A)

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Giacomo Della Verde et al.
Life science alliance, 5(3) (2021-12-15)
Fms-like tyrosine kinase 3 (Flt3) is a regulator of hematopoietic progenitor cells and a target of tyrosine kinase inhibitors. Flt3-targeting tyrosine kinase inhibitors can have cardiovascular side effects. Flt3 and its ligand (Flt3L) are expressed in the heart, but little
Lilija Wehling et al.
eLife, 11 (2022-10-19)
The Hippo signaling pathway controls cell proliferation and tissue regeneration via its transcriptional effectors yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ). The canonical pathway topology is characterized by sequential phosphorylation of kinases in the cytoplasm that defines
M L Brown Lobbins et al.
Clinical and experimental immunology, 191(1), 84-95 (2017-09-09)
Peripheral blood mononuclear cells taken from patients with scleroderma express increased levels of interleukin (IL)-13. Moreover, the expression of matrix metalloproteinase-1 (MMP-1) from involved scleroderma skin fibroblasts is refractory to stimulation by tumour necrosis factor (TNF)-α. To elucidate the mechanism(s)
Jianbin Su et al.
Frontiers in pharmacology, 13, 857081-857081 (2022-04-05)
Microglia are key components of the central innate immune system. The over-activation of microglia, which occurs in nervous system disorders, is usually accompanied with retractions of their ramified processes. Reversing of microglial process retraction is a potential strategy for the
Gabriel Luta et al.
International journal of molecular sciences, 22(8) (2021-05-01)
In the latest years, there has been an increased interest in nanomaterials that may provide promising novel approaches to disease diagnostics and therapeutics. Our previous results demonstrated that Carbon-dots prepared from N-hydroxyphthalimide (CD-NHF) exhibited anti-tumoral activity on several cancer cell

相关内容

Human Kinome Poster: The InhibitorSelect™ Protein Kinase Inhibitor Libraries provide broad coverage of the human kinome as shown here. The depicted human kinome dendrogram of 518 kinases are classified into five broad groups, 90 families, and 145 subfamilies. Inhibitor coverage was assigned based upon published data related to potency (IC50, EC50, Kd, etc.) for individual kinases harvested from the literature. Colored dots denote which library contains an inhibitor with demonstrated potent activity against the designated kinase and do not necessarily reflect known specificity of the inhibitor. Coverage of lipid and atypical kinases are depicted as a separate dendrogram. As shown, Calbiochem® Protein Kinase Inhibitor Libraries cover all major kinase families including TK, CMGC, CAMK, AGC, CK1, STE, TKL, as well as Lipid or Atypical kinase families.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持